Navigation Links
Hyaluronic Acid Knee Procedures Grow 38% from Q3 2006 to Q3 2007
Date:11/26/2007

Orthopedic Surgeons and Rheumatologists Performing More Procedures

WALTHAM, Mass., Nov. 26 /PRNewswire/ -- Millennium Research Group's US Hyaluronic Acid (HA) Viscosupplementation Marketrack(TM) service, which captures data from both orthopedic surgeons and rheumatologists, shows that both groups provided more HA knee injections in Q3 2007 compared to Q3 2006. While treatments are growing in both groups, there are substantial differences in the products they use in these procedures.

In the survey sample, from Q3 2006 to Q3 2007, average quarterly orthopedic surgeon HA knee injection volumes jumped from 62 to nearly 85. Similarly, over the same time period, average quarterly HA knee injections for rheumatologists increased from 54 to over 75. Fueling this growth is the growing aging population, which is expanding the potential patient pool for HA viscosupplementation each year. In addition, expanding patient awareness of the benefits of HA viscosupplementation injections is also increasing the number of patients seeking and ultimately receiving treatment.

"While both groups' injection numbers are rising, they are using different products," says Kevin Flewwelling, Senior Analyst at MRG. "It turns out that in Q307, orthopedic surgeons mostly used Genzyme's Synvisc, which represented nearly 39% of the total injections administered by orthopedic surgeons. Rheumatologists, on the other hand, tended to use sanofi aventis' Hyalgan most often, which accounted for almost 36% of the total injections administered by this group."

When both groups were asked to rank the most important reasons for prescribing HA viscosupplementation, orthopedic surgeons ranked product efficacy as their number one reason, while rheumatologists reported long-term pain relief as their first priority.

About Hyaluronic Acid Viscosupplementation Marketrack(TM)

HA Viscosupplementation Marketrack(TM) gathers data from 260 orthopedic surgeons, rheumatologists, and other practitioners performing HA Viscosupplementation procedures throughout the US. Data is collected on a quarterly basis. Marketrack subscribers receive thousands of data points, including usage (units, average selling price, and revenue), procedure volumes, distribution channels, competitors, and brand information (Hyalgan, Euflexxa, Orthovisc, Supartz, Synvisc, and others). The project also covers information on the competing corticosteroid markets.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of ... health care systems, in terms of costs and resources. However, ... the development of innovative and efficient therapies that demonstrate higher ... types of cancer treatments, a growing number of patients receiving ...
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
(Date:3/22/2017)... , March 22, 2017 Oramed ... ( www.oramed.com ), a ... oral drug delivery systems, announced today that Dr. ... will deliver a presentation titled, "Oral Insulin for ... Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017   ... of next-generation cancer therapeutics designed to target cancer stemness ... Patricia S. Andrews as Chief Executive Officer, ... will succeed Chiang J. Li , M.D., FACP, ... company ten years ago. Under his leadership, Boston Biomedical ...
Breaking Biology Technology:
(Date:3/20/2017)... , March 20, 2017 PMD Healthcare announces ... spirometer and Wellness Management System (WMS), a remote, real-time ... in 2010, PMD Healthcare is a Medical Device, Digital ... mission dedicated to creating innovative solutions that empower people ... that intent focus, PMD developed the first ever personal ...
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , ... Well Made Simple," and 23andMe , the leading ... better food choices.  Zipongo can now provide customers with ... preferences, health goals and biometrics, but also genetic markers ... choices. Zipongo,s personalized food decision support platform ...
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
Breaking Biology News(10 mins):